Book contents
- The Obstetric Hematology Manual
- The Obstetric Hematology Manual
- Copyright page
- Dedication
- Contents
- Contributors
- Preface to the Second Edition
- Section 1 Physiological Changes in Pregnancy
- Section 2 Cytopenia
- Section 3 Inherited Red Cell Disorders
- Section 4 Fetal Maternal Alloimmune Syndromes
- Section 5 Thromboembolism and Anticoagulation
- Section 6 Thrombophilia and Fetal Loss
- Section 7 Hemorrhagic Disorders
- Section 8 Microangiopathies
- Section 9 Malignant Conditions
- Index
- References
Section 8 - Microangiopathies
Published online by Cambridge University Press: 01 February 2018
Book contents
- The Obstetric Hematology Manual
- The Obstetric Hematology Manual
- Copyright page
- Dedication
- Contents
- Contributors
- Preface to the Second Edition
- Section 1 Physiological Changes in Pregnancy
- Section 2 Cytopenia
- Section 3 Inherited Red Cell Disorders
- Section 4 Fetal Maternal Alloimmune Syndromes
- Section 5 Thromboembolism and Anticoagulation
- Section 6 Thrombophilia and Fetal Loss
- Section 7 Hemorrhagic Disorders
- Section 8 Microangiopathies
- Section 9 Malignant Conditions
- Index
- References
- Type
- Chapter
- Information
- The Obstetric Hematology Manual , pp. 265 - 292Publisher: Cambridge University PressPrint publication year: 2018
References
References
Kuklina, EV, Ayala, C, Callaghan, WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstetrics and Gynecology 2009; 113: 1299–1306.CrossRefGoogle ScholarPubMed
World Health Organization. Maternal Mortality in 2005: Estimates Developed by WHO, UNICEF, UNIFPA and the World Bank. Geneva, World Health Organization; 2007.Google Scholar
RCOG. The Investigation and Management of the Small-for-Gestational Age Fetus. Green-Top Guideline No. 31, 2nd Edition. London: Royal College of Obstetricians and Gynaecologists; 2013, Minor revisions – January 2014.Google Scholar
Preeclampsia Foundation. http://www.preeclampsia.org/the-news/1-latest-news/299-new-guidelines-in-preeclampsia-diagnosis-and-care-include-revised-definition-of-preeclampsia http://www.preeclampsia.org/the-news/1-latest-news/299-new-guidelines-in-pre-eclampsia-diagnosis-and-care-include-revised-definition-of-pre-eclampsiaGoogle Scholar
Bhide, A, Rana, R, Dhavilkar, M et al. The value of the urinary protein: creatinine ratio for the detection of significant proteinuria in women with suspected preeclampsia. Acta Obstetricia et Gynecologica Scandinavica 2015; 94(5): 542–546.CrossRefGoogle ScholarPubMed
Roberts, JM, Gammill, HS. Preeclampsia: recent insights. Hypertension 2005; 46: 1243–1249.Google Scholar
Maynard, SE, Min, JY, Mercham, J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigations 2003; 111: 649–658.Google Scholar
Lu, F, Longo, M, Tamayo, E et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. American Journal of Obstetrics and Gynecology 2007; 196: 396.Google Scholar
Li, B, Ogasawara, AK, Yang, R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002; 39: 1095–1100.CrossRefGoogle ScholarPubMed
Gilbert, JS, Babcock, SA, Granger, JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50: 1142–1147.Google Scholar
Levine, RJ, Lam, C, Qian, C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England Journal of Medicine 2006; 355: 992–1005.CrossRefGoogle ScholarPubMed
Venkatesha, S, Toporsian, M, Lam, C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine 2006; 12: 642–649.CrossRefGoogle Scholar
Masuyama, H, Nakatsukasa, H, Takamoto, N, Hiramatsu, Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1 and adipocytokines in preeclampsia. Journal of Clinical and Endocrinological Metabolism 2007; 92: 2672–2679.CrossRefGoogle ScholarPubMed
Redman, CW, Sacks, GP, Sargent, IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. American Journal of Obstetrics and Gynecology 1999; 180: 499–506.Google Scholar
Alijotas-Reig, J, Palacio-Garcia, C, Llurba, E, Vilardell-Tarres, M. Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review. Fertility and Sterility 2013; 99(2): 441–449. doi: 10.1016/j.fertnstert.2012.10.009. Epub 2012 Nov 2.CrossRefGoogle ScholarPubMed
Irgens, HU, Reiseter, L, Irgens, LM, Lie, RT. Long-term mortality of mothers and fathers after pre-eclampsia: population based cohort study. British Medical Journal 2001; 323: 1213–1217.CrossRefGoogle ScholarPubMed
Barker, DJB (ed.) Foetal and Infant Origins of Adult Disease. London: BMJ Publishing Group; 1992.Google Scholar
Magnussen, EB, Vatlen, LJ, Lund-Nilsen, et al. Pregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. British Medical Journal 2007; 225: 978–981.Google Scholar
Berends, AL, de Groot, CJM, Sijbrands, EJ et al. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension 2008; 51: 1034–1041.Google Scholar
Aykas, F, Solak, Y, Erden, A et al. Persistence of cardiovascular risk factors in women with previous preeclampsia: a long-term follow-up study. Journal of Investigative Medicine 2015; 63(4): 641–645.CrossRefGoogle ScholarPubMed
Liu, X, Olsen, J, Agerbo, E et al. Maternal preeclampsia and childhood asthma in the offspring. Pediatric Allergy and Immunology 2015; 26(2): 181–185. doi: 10.1111/pai.12344.CrossRefGoogle ScholarPubMed
Walker, CK, Krakowiak, P, Baker, A et al. Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay. JAMA Pediatrics 2015; 169(2): 154–162.CrossRefGoogle ScholarPubMed
Rasmussen, S, Irgens, LM. History of fetal growth restriction is more strongly associated with severe rather than milder pregnancy-induced hypertension. Hypertension 2008; 51: 1231–1238.CrossRefGoogle ScholarPubMed
Huppetz, B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51: 970–975.CrossRefGoogle Scholar
Sood, R, Kalloway, S, Mast, AE, Hilard, CJ, Weiler, H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 2006; 107(8): 3173–3181.Google Scholar
Song, J, Li, Y, An, RF. Identification of early-onset preeclampsia-related genes and microRNAs by bioinformatics approaches. Reproductive Sciences 2015; 22(8):954–963.Google Scholar
Salmon, JE, Heuser, C, Triebwasser, M et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Medicine 2011; 8(3): e1001013.Google Scholar
Dekker, GA, de Vries, JI, Doelitzsch, PM, Huijgens, PC, von Blomberg, BM, Jakobs, C, van Geijn, HP. Underlying disorders associated with severe early-onset preeclampsia. American Journal of Obstetrics and Gynecology 1995; 173(4): 1042–1048.CrossRefGoogle ScholarPubMed
Papageorgiou, AT, Yu, CK, Bindra, R, Pandis, G, Nicolaides, KH. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks’ of gestation. Ultrasound Obstetrics and Gynecology 2001; 18: 441–449.CrossRefGoogle Scholar
Chappell, LC, Seed, PT, Briley, A et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. American Journal of Obstetrics and Gynecology 2002; 187: 127–136.CrossRefGoogle ScholarPubMed
Hund, M, Allegranza, D, Schoedl, M et al. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth 2014; 14: 324. doi: 10.1186/1471–2393-14–324.Google Scholar
Palomaki, GE, Haddow, JE, Haddow, HR et al. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenatal Diagnosis 2015; 35(4): 386–393. doi: 10.1002/pd.4554.Google Scholar
CLASP. A randomised trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative low dose Aspirin Study in Pregnancy) Collaborative Group. The Lancet 1994; 343: 619–629.Google Scholar
Askie, LM, Duley, L, Henderson-Smart, DJ, Stewart, LA. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet 2007; 369: 1791–1798.Google Scholar
Askie, L, Duley, L, Henderson-Smart, D, Stewart, L. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet 2007; 369: 1791–1798.CrossRefGoogle ScholarPubMed
Bates, SM, Greer, IA, Middeldorp, S, Veenstra, DL, Prabulos, AM, Vandvik, PO. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S–e736S.Google Scholar
Moore, GS, Allshouse, AA, Post, AL, Galan, HL, Heyborne, KD. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. Journal of Perinatology 2015; 35(5): 328–331. doi: 10.1038/jp.2014.214Google Scholar
Li, C, Raikwar, NS, Santillan, MK, Santillan, DA, Thomas, CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta 2015; 36(4): 446–453.Google Scholar
Mello, G, Parretti, E, Fatini, C et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 86–91.CrossRefGoogle ScholarPubMed
Maki, M, Kobayashi, T, Terao, T et al. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group. Thrombosis and Hemostasis 2000; 84: 583–590.CrossRefGoogle ScholarPubMed
International Clinical Trials Registry Platform. Statins to Ameliorate early onset Pre-eclampsia StAMP. 10. ISRCTN Register; 2009. http://www.controlled-trials.com/ISRCTN23410175 (accessed December 2013).Google Scholar
Costantine, MM, Cleary, K; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric–Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstetrics and Gynecology 2013; 121(2 p. 1): 349–353.Google Scholar
Bateman, BT, Hernandez-Diaz, S, Fischer, MA et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035.Google Scholar
Kakigano, A, Tomimatsu, T, Mimura, K et al. Drug repositioning for preeclampsia therapeutics by in vitro screening: phosphodiesterase-5 inhibitor vardenafil restores endothelial dysfunction via induction of placental growth factor. Reproductive Sciences 2015; 22(10): 1272–1280.CrossRefGoogle ScholarPubMed
Doyle, LW, Crowther, CA, Middleton, P et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009; 1: CD004661.Google Scholar
McCoy, S, Baldwin, K. Pharmacotherapeutic options for the treatment of preeclampsia. American Journal Health-System Pharmacy 2009; 66: 337–344.CrossRefGoogle ScholarPubMed
Woudstra, DM, Chandra, S, Hofmeyr, GJ, Dowswell, T. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database of Systematic Reviews 2010; (9): CD008148.Google Scholar
Mao, M, Chen, C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: A meta-analysis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2015; 21: 3777–3783.Google Scholar
References
Rangarajan, S, Kessler, C, Aledort, L. The clinical implications of ADAMTS13 function: the perspectives of hemostaseologists. Thrombosis Research 2013; 132(4): 403–407.Google Scholar
Delmas, Y, Helou, S, Chabanier, P et al. Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease. BMC Pregnancy Childbirth 2015; 15: 137.Google Scholar
Velauthar, L, Plana, MN, Kalidindi, M et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound in Obstetrics and Gynecology 2014; 43(5): 500–507.Google Scholar
Naljayan, MV, Karumanchi, SA. New developments in the pathogenesis of preeclampsia. Advances in Chronic Kidney Disease 2013; 20(3): 265–270.Google Scholar
Scully, M, Hunt, BJ, Benjamin, S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology 2012; 158(3): 323–335.Google Scholar
Sadler, JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112(1): 11–18.CrossRefGoogle ScholarPubMed
Moatti-Cohen, M, Garrec, C, Wolf, M et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119(24): 5888–5897.Google Scholar
Scully, M, Thomas, M, Underwood, M et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014; 124(2): 211–219.Google Scholar
Sanchez-Luceros, A, Farias, CE, Amaral, MM et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thrombosis and Hemostasis 2004; 92(6): 1320–1326.Google Scholar
Lattuada, A, Rossi, E, Calzarossa, C et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Hematologica 2003; 88(9): 1029–1034.Google ScholarPubMed
Narayanan, P, Jayaraman, A, Rustagi, RS et al. Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange. International Journal of Hematology 2012; 96(1): 122–124.CrossRefGoogle Scholar
Shamseddine, A, Saliba, T, Aoun, E et al. Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. Journal of Clinical Apheresis 2004; 19(3): 119–124.Google Scholar
Ozkan, S, Ceylan, Y, Ozkan, OV et al. Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy. World Journal of Gastroenterology 2015; 21(23): 7134–7141.CrossRefGoogle ScholarPubMed
Kia, L, Rinella, ME. Interpretation and management of hepatic abnormalities in pregnancy. Clinical Gastroenterology and Hepatology 2013; 11(11): 1392–1398.Google Scholar
Sibai, BM. Imitators of severe preeclampsia. Obstetrics and Gynecology 2007; 109(4): 956–966.Google Scholar
Caprioli, J, Noris, M, Brioschi, S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108(4): 1267–1279.Google Scholar
Fakhouri, F, Vercel, C, Fremeaux-Bacchi, V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clinical Journal of the American Society of Nephrology 2012; 7(12): 2100–2106.Google Scholar
Tsai, HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Seminars in Thrombosis and Hemostasis 2012; 38: 469–482.CrossRefGoogle Scholar
Panelius, J, Meri, S. Complement system in dermatological diseases – fire under the skin. Frontiers of Medicine 2015; 2: 3. https://doi.org/10.3389/fmed.2015.00003.Google ScholarPubMed